The aim of this Research Topic was to accelerate pioneering research and deepen our understanding of endocrine-related cancers. By spotlighting groundbreaking studies on targeted therapies, biomarker ...

We don't have biomarkers to guide us ... CDK4/6 progression treatment strategies versus standard-of-care, single-agent endocrine therapy. The authors identified 18 studies comprising a total ...

New DESTINY-Breast06 analysis showed trastuzumab deruxtecan doubled PFS versus chemotherapy in patients with rapid ...

Targeting the estrogen receptor and HER2 pathways improved progression-free survival in patients with HR-positive, ...

A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer ...

As recently as last month, Lexicon Pharmaceuticals Inc. was holding out hope regarding the NDA for Zynquista (sotagliflozin) as an adjunct to insulin therapy for glycemic control in adults with type 1 ...

Four oncologists from the Sarah Cannon Research Institute in Tennessee shared with Fox News Digital what they see as the most ...

Seven in vitro studies evaluate the “effects of pesticides on the anatomy and physiology of hepatocytes and adipocytes” and ...

The major advancements these techniques have brought about and examples of their applications in cancer biomarker discovery will be presented in this review, so that readers can appreciate the ...